Ann Hynes
Stock Analyst at Mizuho
(4.36)
# 376
Out of 5,111 analysts
272
Total ratings
63.73%
Success rate
12%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Outperform | $88 → $95 | $79.69 | +19.21% | 12 | Dec 10, 2025 | |
| ARDT Ardent Health | Maintains: Outperform | $20 → $13 | $8.90 | +46.07% | 3 | Nov 18, 2025 | |
| SGRY Surgery Partners | Maintains: Outperform | $28 → $22 | $15.44 | +42.49% | 3 | Nov 17, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $420 → $400 | $360.67 | +10.90% | 6 | Nov 4, 2025 | |
| HCA HCA Healthcare | Maintains: Outperform | $475 → $505 | $476.98 | +5.87% | 22 | Oct 27, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $559.13 | +17.15% | 5 | Oct 24, 2025 | |
| THC Tenet Healthcare | Maintains: Outperform | $194 → $225 | $197.32 | +14.03% | 16 | Oct 17, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $190 → $210 | $184.11 | +14.06% | 16 | Oct 17, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $320 | $263.33 | +21.52% | 16 | Oct 17, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $9 | $16.06 | -43.96% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $155 → $174 | $198.15 | -12.19% | 3 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $32 | $35.96 | -11.01% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $430 | $341.10 | +26.06% | 21 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $345 | $274.74 | +25.57% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $40.45 | -1.11% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $22 | $14.22 | +54.71% | 12 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $223.63 | +0.61% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $184.37 | +22.04% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $166.50 | +98.20% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $22.69 | -33.89% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $199.96 | -39.99% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $19.88 | +40.85% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $107.59 | -11.70% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $277.15 | +38.91% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $223.87 | -10.66% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $1.95 | +13,643.59% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $823.01 | -38.64% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.40 | +3,971.43% | 1 | Sep 21, 2017 |
CVS Health
Dec 10, 2025
Maintains: Outperform
Price Target: $88 → $95
Current: $79.69
Upside: +19.21%
Ardent Health
Nov 18, 2025
Maintains: Outperform
Price Target: $20 → $13
Current: $8.90
Upside: +46.07%
Surgery Partners
Nov 17, 2025
Maintains: Outperform
Price Target: $28 → $22
Current: $15.44
Upside: +42.49%
Elevance Health
Nov 4, 2025
Maintains: Outperform
Price Target: $420 → $400
Current: $360.67
Upside: +10.90%
HCA Healthcare
Oct 27, 2025
Maintains: Outperform
Price Target: $475 → $505
Current: $476.98
Upside: +5.87%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $559.13
Upside: +17.15%
Tenet Healthcare
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $197.32
Upside: +14.03%
Quest Diagnostics
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $184.11
Upside: +14.06%
Labcorp Holdings
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $263.33
Upside: +21.52%
Fortrea Holdings
Oct 17, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $16.06
Upside: -43.96%
Oct 17, 2025
Maintains: Neutral
Price Target: $155 → $174
Current: $198.15
Upside: -12.19%
Oct 17, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $35.96
Upside: -11.01%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $341.10
Upside: +26.06%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $274.74
Upside: +25.57%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $40.45
Upside: -1.11%
Aug 14, 2025
Maintains: Neutral
Price Target: $32 → $22
Current: $14.22
Upside: +54.71%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $223.63
Upside: +0.61%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $184.37
Upside: +22.04%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $166.50
Upside: +98.20%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $22.69
Upside: -33.89%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $199.96
Upside: -39.99%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $19.88
Upside: +40.85%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $107.59
Upside: -11.70%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $277.15
Upside: +38.91%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $223.87
Upside: -10.66%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $1.95
Upside: +13,643.59%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $823.01
Upside: -38.64%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.40
Upside: +3,971.43%